

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions and listings of the claims.

1-67. (Canceled).

68. (Currently Amended) A quick release pharmaceutical composition for oral administration comprising ~~a therapeutically and/or prophylactically active substance which has a solubility of at the most 0.1 % w/v in 0.1 N hydrochloric acid at room temperature~~ lornoxepam or a pharmaceutically acceptable salt, complex or prodrug thereof,

the composition being in the form of a particulate composition or being based on a particulate composition, wherein either the particles of the particulate composition used in the manufacture of the composition have a mean particle size of at the most 250 micrometers, or

at least 50% w/w of the particles of the particulate composition used in the manufacture of the composition pass through a 180 micrometer sieve;

wherein the quick release pharmaceutical composition contains the active substance in contact with an alkaline substance; and

the composition, when tested in accordance with the dissolution method I defined herein employing 0.07 N hydrochloric acid as dissolution medium, releases at least 50% w/w of the active substance within the first 20 minutes of the test.

69. (Canceled).

70. (Canceled)

71. (Currently Amended) A composition according to claim 68 ~~or 70~~, wherein the composition, when subjected to dissolution method I as defined herein employing 0.07 N hydrochloric acid as dissolution medium, releases at least 55% w/w of total amount of active substance present in the composition within the first 20 minutes of the test.

72. (Currently Amended) A composition according to claim 68 ~~or 70~~, wherein the solubility of the therapeutically and/or prophylactically active substance in 0.1 N hydrochloric acid at room temperature is at the most 0.05% w/v.

73-74. (Canceled).

75. (Currently Amended) A composition according to claim 68 ~~or 70~~, further comprising at least one pharmaceutically acceptable excipient.

76. (Previously presented) A composition according to claim 75, wherein the at least one pharmaceutically acceptable excipient is selected from the group consisting of binders, disintegrants, fillers and diluents.

77. (Previously presented) A composition according to claim 76, wherein the composition comprises a filler having binding properties.

78. (Previously presented) A composition according to claim 77, wherein the filler having binding properties is selected from the group consisting of lactose, sugar derivatives, calcium carbonate (CaCO_3), tricalcium phosphate ($\text{Ca}_3(\text{PO}_4)_2$), calcium hydrogen phosphate (CaHPO_4) and/or mixtures thereof.

79. (Previously presented) A composition according to claim 76, wherein the filler having binding properties is calcium hydrogen phosphate.

80. (Previously presented) A composition according to claim 76, wherein the filler having binding properties as raw material has a mean particle size of at the most 140 μm .

81. (Canceled).

82. (Previously presented) A composition according to claim 108, wherein the alkaline substance is an antacid or an antacid-like substance selected from the group consisting of sodium hydrogen carbonate, magnesium carbonate, magnesium hydroxide and magnesium metasilicate aluminate or mixtures thereof.

83. (Previously presented) A composition according to claim 82, wherein the mean particle size of the antacid-like substance as raw material is at the most 250 μm .

84. (Canceled).

85. (Canceled).

86. (Canceled)

87. (Canceled).

88. (Currently Amended) A composition according to claim 68 ~~or 70~~, comprising a further active drug substance.

89. (Currently Amended) A composition according to claim 68 ~~or 70~~, wherein the further active drug substance is an antidepressant, an opioid, a prostaglandine analogue, a glucocorticosteroid, a cytostaticum, a H_2 receptor antagonist, a proton pump inhibitor and/or an antacidum.

90. (Previously presented) A composition according to claim 88, wherein the further active drug substance is misoprostol, methotrexate, cimetidine, ranitidine, pantoprazole, omeprazole, lansoprazole, paracetamol, penicillaminutese, sulfasalazine and/or auranorfin.

91. (Currently Amended) A composition according to claim 68 ~~or 70~~, in unit dosage form, wherein the unit dosage of the composition comprises from 1 to 32 mg of the therapeutically and/or prophylactically active substance.

92. (Currently Amended) A composition according to claim 68 ~~or 70~~, in unit dosage form, wherein the unit dosage comprises from 1 mg to 1.6 g of the therapeutically and/or prophylactically active substance.

93. (Currently Amended) A composition according to claim 68 ~~or 70~~, wherein the therapeutically and/or prophylactically active substance is lornoxicam and a unit dosage of the composition contains 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32 or 36 mg of lornoxicam.

94. (Currently Amended) A composition according to claim 68 ~~or 70~~, wherein the water content in the composition is at the most 5% w/w determined by the LOD (loss on drying) method described herein.

95. (Currently Amended) A composition according to claim 68 ~~or 70~~, comprising sodium hydrogen carbonate.

96. (Currently Amended) A composition according to claim 68 ~~or 70~~, comprising calcium hydrogen phosphate.

97-107. (Cancelled)

108. (Previously Presented) A composition according to claim 81, wherein the alkaline substance is an antacid or an antacid-like substance.

109. (Currently Amended) A composition according to claim 68 ~~or 70~~, wherein when tested according to the dissolution method I defined herein employing 0.07 N hydrochloric acid as dissolution medium, releases at least 80% w/w of the active substance within the first 20 minutes of the test.

110. (Cancelled).

111. (Currently Amended) A composition according to claim 68 ~~or 70~~, wherein the quick release pharmaceutical composition is a coated tablet.

112-114. (Cancelled)

115. (Previously presented) The composition of claim 68, comprising Lornoxicam, sodium hydrogen carbonate, microcrystalline cellulose, calcium hydrogen phosphate anhydrous, L-HPC, hydroxy propyl cellulose, water, ethanol, and calcium stearate.

116. (Previously presented) The composition of claim 68, comprising Lornoxicam, sodium hydrogen carbonate, microcrystalline cellulose, calcium hydrogen phosphate anhydrous, L-HPC, hydroxy propyl cellulose, and calcium stearate.

117. (Canceled).

118. (Canceled).

119. (Previously Presented) The composition of Claim 68, wherein the composition has a mechanical strength to enable the composition to be coated using traditional coating equipment.

120. (Canceled).

121. (Previously presented) The composition of claim 68, further comprising a filler having binding properties, wherein the composition comprising the binder in the form of tablets having a diameter of 9.5 mm when subjected to a crushing strength test in accordance with Ph. Eur. has a crushing strength of at least about 50N.

122. (Canceled).

123. (Previously presented) The composition of claim 68, wherein at least 50% w/w of the particles of the particulate composition used in the manufacture of the composition pass through a 180 micrometer sieve.

124. (Canceled).

125. (Previously presented) The composition of claim 68, wherein the particles of the particulate composition comprises a granulate.

126. (Canceled).